ArticleProstate international2025
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomaterials and Nanomedicine for Mucosal Repair and Inflammation Control in Interstitial Cystitis/Bladder Pain Syndrome: An Extensive Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benefit of pentosan polysulfate sodium (PPS) for reducing chronic pain and lower urinary tract symptomin patients with interstitial cystitis/bladder pain syndrome (IC/BPS) remains inconclusive with modest effect. We aimed to evaluate the impact of PPS on improvement of lower urinary tract symptom based on the International Prostate Symptom Score (IPSS), quality of life (QoL), and uroflowmetry (UFM) in patients with IC/BPS. Materials and methods: A total of 204 patients who were prescribed oral PPS for IC/BPS from October 2006 to May 2021 were retrospectively reviewed. Patients were divided by age for treatment effect comparison. Linear mixed models were utilized to evaluate improvements in IPSS, QoL, and UFM parameters after PPS treatment. Results: There were significant gains in total IPSS (-0.335, Conclusions: PPS provides clinical benefits in urinary symptoms voiding symptoms and QoL over time, arriving plateau within 3 months. Such benefits based on the IPSS tend to be more evident in younger patients, suggesting that PPS mostly benefits early treatment if suspected for IC/BPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.